Objective: Hot flashes are a common symptom in breast cancer survivors that can negatively impact quality of life. Preliminary data suggested that magnesium might be used as an effective low-cost treatment of hot flashes with minimal adverse effects.
H ot flashes continue to be the most common symptom associated with menopause and are experienced by about 75% of women. 1, 2 Although some might consider hot flashes as a Bbenign[ symptom, they can be a source of distress, can disrupt sleep, can negatively impact the ability to function in various life activities, and can cause changes in jobs or work schedules. 3 Estrogen-based and/or progesteronebased therapy can offer an 80% to 90% reduction in hot flashes. 4<7 However, hormone-based treatments are often not recommended for women with a history of breast cancer because of concerns with cancer recurrence and cancer-related risk factors such as a history of thrombotic events. Therefore, hot flashes in female breast cancer survivors are more difficult to treat than they are in other women. 8 Tamoxifen therapy is associated with hot flashes in more than 50% of women, and the incidence of hot flashes after treatment with aromatase inhibitors has been reported to be 34% to 58%. 4, 9, 10 The most effective nonhormone pharmacologic therapiesVantidepressants and anticonvulsantsVoffer about a 50% reduction in hot flashes, 3, 9, 11, 12 but they do have some undesired adverse effects such as dizziness, dry mouth, trouble sleeping, somnolence, and nausea. 13 Furthermore, antidepressants are viewed with stigma by many individuals. Although herbs and dietary supplements (such as soy, black cohosh, flaxseed, and vitamin E) are popular hot flash remedies, randomized placebo-controlled trials have not proven them to be effective to date. 14<18 Magnesium, a mineral with a long history of medicinal use, has been used to treat hypertension, 19 eclampsia, 20 and other cardiovascular 21 and nerve 22 disorders. Currently, it is most commonly used as a laxative, usually preparing the bowel for surgical operation or diagnostic procedures.
The results of two pilot studies using up to 1,200 mg of magnesium oxide daily suggested that this agent was associated with significant reductions in hot flash symptoms. 23, 24 One open-label pilot study using magnesium oxide up to 800 mg/day and validated methodologies 25 supported that magnesium significantly reduced hot flash score and hot flash frequency compared with baseline values. Of 25 women, 14 women (56%) experienced a greater than 50% reduction in hot flash score and 19 women (76%) had a greater than 25% reduction in hot flash score at the end of 4 weeks of study treatment. The mean weekly hot flash score decreased by 50.4% (P = 0.02).
A second open-label study 24 evaluated 400 mg of magnesium oxide thrice daily for 4 weeks in 22 women undergoing treatment of breast cancer. Ten women (45%) reported relief of hot flashes during this time, and another 10 women (45%) reported experiencing a 50% or greater reduction in hot flashes. The results of these two studies were comparable with the results of pilot studies of other agents that subsequently showed efficacy in phase 3 trials.
Several in vitro studies have suggested a possible relationship between the homeostasis of intracellular magnesium and estrogen and progesterone. 26<30 Although the pathophysiology of hot flashes is still unclear, magnesium seems to be a reasonable link between vasomotor symptoms and meno-pause. Magnesium oxide is inexpensive, generic, and readily available. In addition, no important adverse effects, aside from some diarrhea, have been found within relevant dose ranges in individuals with intact kidney function. Therefore, this current randomized, double-blind, placebo-controlled trial was designed to definitively evaluate the efficacy of oral magnesium oxide for ameliorating hot flash symptoms in women with a history of breast cancer.
METHODS
Postmenopausal women with a history of breast cancer who reported bothersome hot flashes (defined as hot flashes 928 times per week and of sufficient severity to make each woman desire therapeutic intervention) were included in this study. Other inclusion criteria were as follows: presence of hot flashes for at least 30 days before study registration, preserved kidney function (calculated creatinine clearance 930 mL/min), Eastern Cooperative Oncology Group performance status of 0 or 1, and ability to complete questionnaires by oneself or with assistance.
Women were excluded if they were receiving antineoplastic chemotherapy, estrogenic agents, progesterone analogs, androgens, gabapentin, or antidepressants. Other exclusion criteria were as follows: a history of allergic reaction or other adverse reactions to magnesium, concurrent use of magnesium for any indication, any condition that might affect magnesium levels (including diabetes, Crohn's disease, diarrheal disease, and alcohol abuse), or use of diuretics, corticosteroids, or bile acid sequestrants. Women participating in yoga or acupuncture for relief of hot flashes were also excluded. Each participant signed an institutional review boardYapproved, protocol-specific informed consent form in accordance with federal and institutional guidelines.
Women were stratified by age, concurrent use of antiestrogen therapy, and daily frequency of hot flashes, and randomized into four double-blind treatment groups of 800 or 1,200 mg of magnesium oxide daily. The two placebo groups were assigned either two or three capsules, corresponding to the same number of capsules for each magnesium oxide dose (each magnesium oxide capsule was 400 mg) at a 2:2:(1:1) ratio.
Self-reported validated survey instruments 25 and telephone interviews were used to collect data on the frequency and severity of hot flashes and on potential toxicities. The first week after enrollment was used to collect information on baseline characteristics of hot flashes and on symptoms that might have subsequently been construed as potential magnesium toxicities. These symptoms were queried on a symptom experience diary that asked women to rate, on a scale of 0 to 10, the following: diarrhea, constipation, other gastrointestinal symptoms, constitutional symptoms, mood, concentration, and level of distress attributable to hot flashes. Women started treatment after the baseline week at a dose of one tablet daily, which was titrated up by one tablet weekly to a total of two or three tablets of allocated treatment per protocol. The same data that were collected on the baseline week were also collected in the same manner at the end of each treatment week. Serum magnesium concentrations were obtained before study medication and during the last week of treatment in the first 150 women. Intrapersonal changes in serum magnesium concentrations were compared among the three study arms. This trial was monitored at least twice annually by a Data and Safety Monitoring Board, a standing committee composed of individuals from within and outside the North Central Cancer Treatment Group (NCCTG)/ Alliance.
Statistical analysis
Hot flashes were measured by the weekly mean hot flash score, 25 which is a composite entity of both frequency and severity of hot flashes (number Â mean severity). Women were randomized using an established procedure of dynamic allocation 31 that balanced the marginal distributions of stratification factors and the clinical site. We did not adjust for site of enrollment in statistical analysis as we did not observe an unusual imbalance. The modified intent-to-treat principle 32 (which excludes cancellation, ineligible women, and those who did not complete any postbaseline questionnaire for primary endpoint) was conducted for primary analysis. The primary endpoint was intrapatient change from baseline in weekly mean hot flash scores during the 8 weeks of treatment. Repeatedmeasures and growth curve models 33 were used to examine the treatment effect of magnesium. To control for multiplicity from multiple treatment arms, we used a gatekeeper procedure, 34 following a fixed-sequence hypothesis testing method, to examine first the higher dose of magnesium versus placebo and then the lower dose of magnesium versus placebo, if the former was statistically significant.
Secondary endpoints included intrapatient changes in (1) hot flash frequency; (2) toxicities, including diarrhea (using Common Terminology Criteria for Adverse Events version 4.0); (3) mood (using the Profile of Mood States) and hot flashYrelated daily interference with activities (using the Symptom Experience Questionnaire and the Hot Flash Related Daily Interfer-ence); and (4) magnesium serum concentrations between magnesium oxide and placebo arms. All scales were converted into 0 to 100 (where 100 represents the best quality of life) for ease of comparison of secondary endpoints. 35 The association of magnesium serum concentrations was explored for the first 150 women only.
With a sample size of 80 women per arm, the study had 80% power to detect a time-averaged clinically meaningful difference of 5.1 points (8.6 for either magnesium arm, 3.1 for placebo arms) for changes in hot flash scores (on a 0-100 scale) using the repeated-measures model with a two-sided 5% significance level. A moderate positive correlation of 0.5 was assumed between repeated measures of weekly hot flash scores during the 8 weeks. The sample size was inflated by 20% to account for participant ineligibility, cancellation, or major violations. Data collection and statistical analyses were conducted by the NCCTG/Alliance Statistics and Data Center. Data quality was ensured by review of data by the NCCTG/Alliance Statistics and Data Center and by the study chairperson following NCCTG/Alliance Statistics and Data Center policies. The analyzed data set was locked on November 11, 2013.
RESULTS

Baseline characteristics
A total of 289 women were enrolled between December 2011 and March 2013, including 10 cancellations, 4 ineligible women, and, additionally, 8 women who did not complete booklets for the primary endpoint (refused, did not return booklet, or dropped out during cycle 1 because of an adverse event; see the Consolidated Standards of Reporting Trials diagram in Fig. 1 ). The study arms had reasonably wellbalanced baseline participant characteristics, as illustrated in Table 1 . No cross-overs or cointerventions were allowed during the treatment period for any of the arms; we are not aware of any cross-overs or cointerventions that occurred. 
Efficacy
Following a modified intent-to-treat principle, 267 women (92%) were available for the primary study analysis. Placebo arms were combined, as per the protocol plan, after determining that there were no differences between the two placebo arms during the protocol period. Mean hot flash scores and hot flash frequencies for each arm are shown in Table 2 , with P values comparing each treatment arm with the combined placebo arms. Changes in mean hot flash scores and hot flash frequencies across time are shown in Figure 2 . All groups experienced reductions in hot flash scores and hot flash frequencies, but the degree of reduction in the treatment groups was similar to that in the placebo group. significant difference in serum magnesium levels was observed between any of the study arms. Furthermore, there was no statistically significant correlation between serum magnesium levels and changes in hot flash symptoms.
Analysis of changes in Profile of Mood States and Hot Flash Related Daily Interference scores did not show significant differences between treatment and placebo groups. No
Toxicity
There were no significant toxicity differences (measured by Common Terminology Criteria for Adverse Events version 4) between the three study arms. Nonetheless, symptom experience diary data revealed an increased incidence of diarrhea in the magnesium arms compared with the placebo arm; correspondingly, constipation was reported less frequently in the magnesium arms. These data are detailed in Table 3 .
DISCUSSION
Despite pilot trial data suggesting that magnesium would be beneficial, the results of this study do not support the study hypothesis that magnesium oxide would decrease hot flashes.
Serum magnesium levels were unchanged after treatment with magnesium and were not associated with changes in hot flash scores. This was the case in another randomized trial, where oral magnesium was shown to be effective in controlling asthma-related symptoms. 36 Considering that serum magnesium is tightly regulated by renal excretion, which can be significantly increased in the setting of high magnesium load, it is likely that serum magnesium is not an optimal surrogate for the intracellular activity of magnesium, regardless of the bioavailability of the agent.
The research group that conducted this current trial has conducted a variety of clinical trials based on anecdotal and/or pilot data suggesting benefits for different proposed treatments. Some of these trials have been positive, demonstrating benefits for megestrol acetate, 37 medroxyprogesterone acetate, 5 venlafaxine, 9 citalopram, 3 pregabalin, 38 fluoxetine, 39 and clonidine. 40 In contrast, this same research group has conducted other trials that unfortunately did not confirm the study hypothesis, as was seen with magnesium oxide in the current study. These negative trials included studies of flaxseed, 18 soy product, 17 black cohosh, 16 and vitamin E. 15 
CONCLUSIONS
This series of trials illustrates the need to conduct welldesigned placebo-controlled trials to clarify the benefits and toxicities of agents showing promise at the pilot phase of hot flash treatment studies. 
